Organogenesis Holdings Inc

Organogenesis Holdings reported a net loss of $96.3 million for the second quarter of 2026, compared to a net loss of $9.4 million in the same period last year. Net revenue fell 58% to $42.8 million, driven by a 61% decline in Advanced Wound Care product revenue to $36.1 million, while Surgical & Sports Medicine revenue decreased 18% to $6.7 million. The company also lowered its full-year 2026 revenue guidance to between $179 million and $215 million, representing a decline of 62% to 68% from 2025. Adjusted EBITDA loss widened to $34.4 million from $3.6 million a year earlier. Cash and equivalents stood at $46.8 million with no outstanding debt as of June 30, 2026.

The regenerative medicine market is projected to surpass US$100 billion within roughly a decade, driven by a shift from tissue replacement to regeneration using biomaterials, cell therapies, and 3D bioprinting. Independent estimates place the broad market in the tens of billions of dollars in 2026, with compound annual growth rates frequently estimated in the high teens to mid-20s percent. Key drivers include aging populations, the diabetes epidemic, rising surgical volumes, and growing demand in aesthetics, partly fueled by GLP-1 weight-loss medications. The sector spans profitable commercial leaders like Integra LifeSciences and Vericel to early-stage platform companies such as Conexeu Sciences, which began trading on Nasdaq in May 2026 with its collagen-based extracellular-matrix platform. Reimbursement policy and regulatory pathways remain critical risks, as illustrated by recent upheaval in the U.S. skin-substitute market affecting companies like Organogenesis and MiMedx.